# A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

> **NCT07037758** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 380 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Tarlatamab
- **DRUG:** AB248

## Key facts

- **NCT ID:** NCT07037758
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2028-03-18
- **Final completion:** 2031-01-18
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07037758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07037758, "A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07037758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*